Trials / Completed
CompletedNCT00054041
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Phase II Evaluation Of SGN-00101 (HSP-E7) Fusion Protein In Women With Cervical Intraepithelial Neoplasia 3, CIN 3
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- Female
- Age
- 17 Years
- Healthy volunteers
- Not accepted
Summary
Vaccines made from antigens may make the body build an immune response to kill abnormal cervical cells and may be effective in preventing cervical cancer. Randomized phase II trial to study the effectiveness of vaccine therapy in preventing cervical cancer in patients who have cervical intraepithelial neoplasia
Detailed description
PRIMARY OBJECTIVES: I. Determine the efficacy of SGN-00101, in terms of complete histologic regression, in patients with grade III cervical intraepithelial neoplasia. II. Determine the toxicity of this drug in these patients. SECONDARY OBJECTIVES: I. Determine change in lesion size in these patients after treatment with this drug. II. Compare histologic response before and after treatment with this drug in these patients. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. Arm I: Patients receive SGN-00101 subcutaneously once on weeks 1, 4, and 8 in the absence of disease progression. Arm II: Patients receive standard care. At week 15, all patients undergo large loop excision of the transformation zone under colposcopy. Patients are followed at 19 weeks, every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 28-84 patients (14-42 per treatment arm) will be accrued for this study within 12-48 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HspE7 | Given subcutaneously |
| PROCEDURE | therapeutic conventional surgery | Undergo large loop excision |
| OTHER | laboratory biomarker analysis | Correlative studies |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2007-01-01
- First posted
- 2003-02-06
- Last updated
- 2013-01-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00054041. Inclusion in this directory is not an endorsement.